Provider of drug discovery platform for different diseases. The products are TBE monoclonal and multispecific antibodies against unique targets, TIM synthetic biologic design for auto-immune diseases, and chronic viral infections MIP unique multi-cyclic peptides with great potency targeting intracellular protein-protein interactions. The company was founded in 2018 and headquartered in King Of Prussia, United States. It has raised $35M in series b funding, with backing from CS Capital, fontuscapital.com, Yuanbio Venture Capital, Yuanhe Holdings, and others. The company operates in the Life Sciences - Oncology, Life Sciences - Life Sciences Platforms and Tools, Life Sciences - Genomics space. Its offerings span Oncology - Drugs - Diversified - Immuno Oncology and Genomics - Applied Genomics - Synthetic Biology.
← All startups
Tavotek
Series BProvider of drug discovery platform for different diseases. The products are TBE monoclonal and multispecific antibodies against unique targets, TIM synthetic biologic design for auto-immune diseases, and chronic viral infections MIP unique multi-cyclic peptides with great potency targeting intracellular protein-protein interactions. The company was founded in 2018 and headquartered in King Of Prussia, United…
About
Business model
Oncology > Drugs > Diversified > Immuno Oncology,
Genomics > Applied Genomics > Synthetic Biology,
Life Sciences Platforms and Tools > Research Services > Genomics
Institutional investors
CS Capitalfontuscapital.comYuanbio Venture CapitalYuanhe HoldingsNew Alliance CapitalGF Xinde Investment ManagementCTS CapitalJuming Venture Capital
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.